• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    PetIQ, Inc. Appoints New CFO

    1/5/22 8:00:00 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care
    Get the next $PETQ alert in real time by email

    EAGLE, Idaho, Jan. 05, 2022 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication and wellness company, today announced the appointment of Zvi Glasman, as its Chief Financial Officer ("CFO"), effective January 3, 2022. Glasman has 20 years of CFO experience supporting high growth companies to drive operational improvements and increased profitability.

    "I am excited to welcome Zvi to PetIQ. He is a strong public company CFO with a track record of success across consumer, manufacturing, and software companies, which will help him make an immediate impact at PetIQ," commented Cord Christensen, PetIQ's Chairman & CEO. "Zvi joins PetIQ at an ideal time as we continue to accelerate our net sales, expand margins, and increase our cash flow generation."

    Prior to joining PetIQ, Glasman held various private and public company CFO positions with his longest tenure at Fox Factory Holdings Corp. ("Fox"), a designer, manufacturer and marketer of high-performance products and systems used primarily on bikes, side-by-side vehicles, ATVs, snowmobiles, motorcycles, automotive, and other off-road and on-road recreational vehicles with international operations. During his twelve year tenure as CFO of Fox, Glasman was an integral member of the executive team having successfully helped transition the business from a privately-held to a publicly-traded company, executing and integrating five strategic M&A transactions, and consistently aligning the organization to deliver on its stated financial objectives for 25 quarters driving both sales growth and margin expansion. Additionally, Glasman was CFO of Faraday Future, an electric vehicle company, where he successfully contributed to its SPAC merger and public company debut with proceeds of approximately $1.0 billion.

    Earlier in his career, Glasman was CFO of two private equity backed companies including Motive Eyewear and Marshall & Swift, where he supported their growth, development and led the successful sale of each business at attractive valuations. Prior to that he held the CFO role at RTI, a venture capital backed software company. He was also Corporate Controller and Vice President of Finance at Creative Computers, a $1 billion direct marketer of computer hardware and software products, and he worked in financial planning and analysis for the Walt Disney Company. Glasman began his career in public accounting as a CPA. He graduated from The Pennsylvania State University with a Bachelor of Science, Finance.

    Glasman succeeds John Newland, who is retiring from his role as CFO. Newland will continue to support the Company through March 2022 as part of its previously announced CFO transition plan.

    About PetIQ

    PetIQ is a leading pet medication and wellness company delivering a smarter way for pet parents to help their pets live their best lives through convenient access to affordable veterinary products and services. The company engages with customers through more than 60,000 points of distribution across retail and e-commerce channels with its branded and distributed medications, which is further supported by its own world-class medications manufacturing facility in Omaha, Nebraska. The company's national service platform, VIP Petcare, operates in over 3,400 retail partner locations in 42 states providing cost effective and convenient veterinary wellness services. PetIQ believes that pets are an important part of the family and deserve the best products and care we can give them.

    Contact: [email protected] or 208.513.1513

    Forward Looking Statements

    This press release contains forward-looking statements that involve risks and uncertainties, such as statements about our plans, objectives, expectations, assumptions or future events. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "believe," "intend," "may," "will," "should," "could" and similar expressions. Forward-looking statements involve estimates, assumptions, known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from any future results, performances, or achievements expressed or implied by the forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time those statements are made or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.

    Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or operating results. The forward-looking statements speak only as of the date on which they are made, and, except as required by law, we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Consequently, you should not place undue reliance on forward-looking statements.



    Primary Logo

    Get the next $PETQ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PETQ

    DatePrice TargetRatingAnalyst
    8/8/2024$30.00 → $31.00Buy → Hold
    Truist
    12/19/2023$22.00Buy
    Jefferies
    9/6/2023$28.00Buy
    Lake Street
    5/13/2022Outperform → Perform
    Oppenheimer
    3/3/2022$32.00 → $29.00Outperform
    Raymond James
    11/30/2021$30.00Buy
    The Benchmark Company
    11/30/2021$30.00Buy
    Benchmark
    11/4/2021$41.00 → $32.00Outperform
    Raymond James
    More analyst ratings

    $PETQ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Glasman Zvi returned 25,800 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - PetIQ, Inc. (0001668673) (Issuer)

    10/28/24 3:10:31 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    Director Huff Scott returned 6,077 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - PetIQ, Inc. (0001668673) (Issuer)

    10/28/24 3:10:13 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    EVP Manufacturing & Sup. Chain Lyon Chad D. returned 10,659 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - PetIQ, Inc. (0001668673) (Issuer)

    10/28/24 3:00:00 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    $PETQ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    PetIQ downgraded by Truist with a new price target

    Truist downgraded PetIQ from Buy to Hold and set a new price target of $31.00 from $30.00 previously

    8/8/24 6:48:12 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    Jefferies initiated coverage on PetIQ with a new price target

    Jefferies initiated coverage of PetIQ with a rating of Buy and set a new price target of $22.00

    12/19/23 6:55:11 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    Lake Street initiated coverage on PetIQ with a new price target

    Lake Street initiated coverage of PetIQ with a rating of Buy and set a new price target of $28.00

    9/6/23 9:07:45 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    $PETQ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PetIQ Names Camillo Pane as Chief Executive Officer

    Accomplished Consumer Goods and Health Care LeaderWould Bring Decades of Leadership Experience to Role EAGLE, Idaho, Feb. 11, 2025 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company"), a leading pet medication, health and wellness company and portfolio company of Bansk Group, is pleased to announce that Camillo Pane would join PetIQ as Chief Executive Officer, effective February 17, 2025. Mr. Pane would succeed Cord Christensen. Mr. Pane's passion for making a difference in the lives of consumers has been a constant focus throughout his more than 30-year career. His drive and commitment in this area has led to strong share gains and profitable growth at a variety of iconic consumer

    2/11/25 10:00:00 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    PetIQ, Inc. Announces Successful Completion of Acquisition by Bansk Group

    EAGLE, Idaho and NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, health and wellness company, today announced the successful completion of its acquisition by Bansk Group ("Bansk"), a consumer-focused private investment firm dedicated to building distinctive consumer brands, in an all-cash transaction valued at approximately $1.5 billion. PetIQ stockholders will receive $31.00 in cash per PetIQ share in accordance with the terms of the transaction. With the completion of the transaction, PetIQ shares no longer trade on and will be delisted from the Nasdaq stock exchange. PetIQ is now a privately held company and co

    10/25/24 8:45:00 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    PetIQ, Inc. Announces Results of Special Meeting of Stockholders

    EAGLE, Idaho, Oct. 22, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, health and wellness company, announced today that at its virtual Special Meeting of Stockholders approximately 80% of its outstanding shares of common stock voted to approve the adoption of the definitive merger agreement (the "Agreement") pursuant to which Bansk Group will acquire all of the outstanding shares of PetIQ's common stock for $31.00 per share, in an all-cash transaction valued at approximately $1.5 billion. "On behalf of PetIQ's Board of Directors, we are excited to announce stockholders' approval of our proposed transaction with Bansk Group, repre

    10/22/24 4:05:00 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    $PETQ
    SEC Filings

    View All

    SEC Form 15-12G filed by PetIQ Inc.

    15-12G - PetIQ, Inc. (0001668673) (Filer)

    11/4/24 4:27:39 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    SEC Form S-8 POS filed by PetIQ Inc.

    S-8 POS - PetIQ, Inc. (0001668673) (Filer)

    10/25/24 9:19:31 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    SEC Form S-8 POS filed by PetIQ Inc.

    S-8 POS - PetIQ, Inc. (0001668673) (Filer)

    10/25/24 9:10:10 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    $PETQ
    Leadership Updates

    Live Leadership Updates

    View All

    PetIQ Names Camillo Pane as Chief Executive Officer

    Accomplished Consumer Goods and Health Care LeaderWould Bring Decades of Leadership Experience to Role EAGLE, Idaho, Feb. 11, 2025 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company"), a leading pet medication, health and wellness company and portfolio company of Bansk Group, is pleased to announce that Camillo Pane would join PetIQ as Chief Executive Officer, effective February 17, 2025. Mr. Pane would succeed Cord Christensen. Mr. Pane's passion for making a difference in the lives of consumers has been a constant focus throughout his more than 30-year career. His drive and commitment in this area has led to strong share gains and profitable growth at a variety of iconic consumer

    2/11/25 10:00:00 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    PetIQ, Inc. Appoints John Pearson to Executive Vice President, Services & Manufactured Products

    EAGLE, Idaho, Aug. 02, 2023 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication and wellness company, today announced that John Pearson, who has served as the Company's Senior Vice President, Head of Services since 2022, has been appointed Executive Vice President, Services & Manufactured Products, a newly created role, effective August 2, 2023. In his new role, Pearson will gain responsibility for PetIQ's manufactured product portfolio, inclusive of the Company's sales and marketing teams, while maintaining his current responsibilities for the Services segment. Pearson will continue to report directly to Michael Smith, President and Chief Ope

    8/2/23 8:00:00 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    Simple Mills Appoints Sheryl O'Loughlin to Board of Directors

    #1 Cookie, Cracker, and Baking Mix Brand in the Natural Channel Taps Industry Veteran to Provide Guidance in Innovation and Sustainability Simple Mills, the company on a mission to advance the holistic health of the planet and its people through delicious, better-for-you foods, today announced the addition of CPG industry veteran, Sheryl O'Loughlin, to its Board of Directors. O'Loughlin is an accomplished entrepreneur, CEO, author, and board member bringing extensive experience leading fast-growing, innovative consumer products companies. In her new role, O'Loughlin will provide strategic counsel and guidance to help support Simple Mills in scaling the company to the next level, creating o

    11/29/22 8:03:00 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    $PETQ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PetIQ Inc.

    SC 13G/A - PetIQ, Inc. (0001668673) (Subject)

    11/14/24 6:36:50 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by PetIQ Inc.

    SC 13G/A - PetIQ, Inc. (0001668673) (Subject)

    11/12/24 5:02:29 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by PetIQ Inc.

    SC 13G/A - PetIQ, Inc. (0001668673) (Subject)

    11/4/24 11:49:14 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    $PETQ
    Financials

    Live finance-specific insights

    View All

    PetIQ, Inc. Reports Second Quarter 2024 Financial Results

    Generates Record Second Quarter 2024 Net Sales and Net IncomeRecord Adjusted EBITDA of $39.0 Million Exceeds Company's Second Quarter 2024 GuidancePetIQ and Bansk Group Sign Definitive Merger Agreement EAGLE, Idaho, Aug. 07, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, product and wellness company, today reported financial results for the second quarter and six months ended June 30, 2024. Cord Christensen, PetIQ's Founder and CEO, commented, "We are very pleased to report another quarter of record financial results. The strength of PetIQ's brands fueled second quarter profitability that exceeded our expectati

    8/7/24 8:01:00 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    PetIQ, Inc. to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

    EAGLE, Idaho, July 17, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, health and wellness company, today announced it will report financial results for the second quarter and six months ended June 30, 2024, on Wednesday, August 7, 2024, after the market close. The Company will host a conference call with members of the executive management team to discuss these results. The conference call is scheduled to begin at 4:30 p.m. ET on Wednesday, August 7, 2024. To listen to the live call participants in North America may dial 833-816-1410 and international participants may dial 412-317-0503. In addition, the call will be broadcast live

    7/17/24 4:05:00 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    PetIQ, Inc. Reports First Quarter 2024 Financial Results

    Reports Record First Quarter 2024 Net Sales of $308.4 MillionAchieves Record First Quarter Net IncomeRecord Adjusted EBITDA Exceeds Company's First Quarter 2024 GuidanceRaises Full Year 2024 Outlook EAGLE, Idaho, May 08, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, product and wellness company, today reported financial results for the first quarter ended March 31, 2024. Cord Christensen, PetIQ's Founder and CEO commented, "We've started 2024 off well with broad-based growth and strong pet parent demand for our product offerings. PetIQ's manufactured brands captured a disproportionate amount of their category market share to fuel

    5/8/24 4:05:00 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care